MX2014001218A - Tratamiento de cancer de mama. - Google Patents

Tratamiento de cancer de mama.

Info

Publication number
MX2014001218A
MX2014001218A MX2014001218A MX2014001218A MX2014001218A MX 2014001218 A MX2014001218 A MX 2014001218A MX 2014001218 A MX2014001218 A MX 2014001218A MX 2014001218 A MX2014001218 A MX 2014001218A MX 2014001218 A MX2014001218 A MX 2014001218A
Authority
MX
Mexico
Prior art keywords
breast cancer
treatment
compounds
iii
treating
Prior art date
Application number
MX2014001218A
Other languages
English (en)
Other versions
MX359664B (es
Inventor
Andrew A Protter
Jennifer Richer
Dawn Cochrane
Original Assignee
Medivation Prostate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014001218(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics Inc filed Critical Medivation Prostate Therapeutics Inc
Publication of MX2014001218A publication Critical patent/MX2014001218A/es
Publication of MX359664B publication Critical patent/MX359664B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente describe el uso de uno o más compuestos que caen dentro del alcance de una o más fórmulas estructurales I, II, II, IV, V, o VI para tratar cáncer de mama negativo triple. Los compuestos útiles par tratar cáncer de mama incluyen aquellos compuestos de las fórmulas I, II, II, IV, V, o VI que inhiben la proliferación de células de cáncer de mama y/o conducen a la muerte de células de cáncer de mama, especialmente cáncer de mama negativo triple.
MX2014001218A 2011-07-29 2012-07-27 Tratamiento de cáncer de mama. MX359664B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (2)

Publication Number Publication Date
MX2014001218A true MX2014001218A (es) 2014-08-22
MX359664B MX359664B (es) 2018-10-05

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001218A MX359664B (es) 2011-07-29 2012-07-27 Tratamiento de cáncer de mama.

Country Status (18)

Country Link
US (4) US9517229B2 (es)
EP (4) EP3430907A1 (es)
JP (2) JP6158180B2 (es)
KR (1) KR101923250B1 (es)
CN (1) CN103997894B (es)
BR (1) BR112014002200A2 (es)
CA (1) CA2843417C (es)
CY (1) CY1121038T1 (es)
DK (1) DK2739153T3 (es)
EA (1) EA028452B1 (es)
ES (1) ES2696074T3 (es)
HK (2) HK1198867A1 (es)
HU (1) HUE040524T2 (es)
MX (1) MX359664B (es)
PL (1) PL2739153T3 (es)
PT (1) PT2739153T (es)
SI (1) SI2739153T1 (es)
WO (1) WO2013066440A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028452B1 (ru) * 2011-07-29 2017-11-30 Медивейшн Простейт Терапьютикс, Инк. Лечение рака молочной железы
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
KR20220025231A (ko) 2012-09-26 2022-03-03 아라곤 파마슈티컬스, 인코포레이티드 비전이성 거세 저항성 전립선암 치료용 항안드로겐
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
KR102221005B1 (ko) 2013-04-17 2021-02-26 시그날 파마소티칼 엘엘씨 전립선암 치료를 위한 디하이드로피라지노-피라진 화합물 및 안드로겐 수용체 길항제를 포함하는 조합 요법
WO2015069266A1 (en) * 2013-11-07 2015-05-14 Flynn Daniel L Methods for inhibiting tie2 kinase useful in the treatment of cancer
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
US10238630B2 (en) 2014-05-28 2019-03-26 Eisai R&D Management Co., Ltd. Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
MX2017007707A (es) 2014-12-12 2018-03-06 Medivation Prostate Therapeutics Llc Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama.
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
CA2977397A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
KR20200070334A (ko) 2017-10-16 2020-06-17 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
BR112022002609A2 (pt) 2019-08-12 2022-08-09 Deciphera Pharmaceuticals Llc Métodos de tratamento de tumores estromais gastrointestinais
KR20220123058A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물
IL293866A (en) 2019-12-30 2022-08-01 Deciphera Pharmaceuticals Llc Compositions of amorphous kinase inhibitors and methods of using them
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DK2444085T3 (en) * 2005-05-13 2015-04-27 Univ California Diarylhydantoinforbindelser as androgenreceptorantagonister for treating cancer
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US20090299640A1 (en) 2005-11-23 2009-12-03 University Of Utah Research Foundation Methods and Compositions Involving Intrinsic Genes
DK2656841T3 (en) * 2006-03-27 2016-12-05 Univ California Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES
RU2449993C2 (ru) 2006-03-29 2012-05-10 Те Риджентс Оф Те Юниверсити Оф Калифорния Диарилтиогидантоиновые соединения
CA2966280A1 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds
US8450290B2 (en) * 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009114534A1 (en) 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
ES2457534T3 (es) 2008-05-30 2014-04-28 The University Of North Carolina At Chapel Hill Perfiles de expresión génica para predecir desenlaces en cáncer de mama
RU2548918C2 (ru) 2009-02-24 2015-04-20 Медивэйшн Простейт Терапьютикс, Инк. Специфические соединения диарилгидантоина и диарилтиогидантоина
EP2416657A4 (en) 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
WO2011022316A1 (en) 2009-08-20 2011-02-24 The Regents Of The University Of Colorado, A Body Corporate Mirnas dysregulated in triple-negative breast cancer
WO2011044327A1 (en) * 2009-10-07 2011-04-14 Medivation Prostate Therapeutics, Inc. Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
US9066963B2 (en) 2011-03-15 2015-06-30 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with anthracycline therapy
EA028452B1 (ru) * 2011-07-29 2017-11-30 Медивейшн Простейт Терапьютикс, Инк. Лечение рака молочной железы
CA2857505A1 (en) 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
CA2882621A1 (en) 2012-08-23 2014-02-27 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
AR092982A1 (es) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
US20140154681A1 (en) 2012-11-12 2014-06-05 Nanostring Technologies, Inc. Methods to Predict Breast Cancer Outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
MX2017007707A (es) 2014-12-12 2018-03-06 Medivation Prostate Therapeutics Llc Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama.

Also Published As

Publication number Publication date
CA2843417C (en) 2018-08-21
EP3791724A1 (en) 2021-03-17
WO2013066440A9 (en) 2013-07-18
EP3610731A1 (en) 2020-02-19
EP2739153A1 (en) 2014-06-11
EA028452B1 (ru) 2017-11-30
EP2739153B1 (en) 2018-08-22
CA2843417A1 (en) 2013-05-10
CN103997894B (zh) 2016-08-24
CN103997894A (zh) 2014-08-20
MX359664B (es) 2018-10-05
HK1201413A1 (en) 2015-09-04
JP2017141269A (ja) 2017-08-17
JP2014524934A (ja) 2014-09-25
CY1121038T1 (el) 2019-12-11
US20140296312A1 (en) 2014-10-02
ES2696074T3 (es) 2019-01-14
US20210069154A1 (en) 2021-03-11
US9517229B2 (en) 2016-12-13
WO2013066440A1 (en) 2013-05-10
HUE040524T2 (hu) 2019-03-28
JP6158180B2 (ja) 2017-07-05
PL2739153T3 (pl) 2019-04-30
US10111861B2 (en) 2018-10-30
KR101923250B1 (ko) 2018-11-28
DK2739153T3 (en) 2018-12-03
HK1198867A1 (en) 2015-06-19
EP2739153A4 (en) 2015-03-11
KR20140107174A (ko) 2014-09-04
SI2739153T1 (sl) 2018-12-31
EP3430907A1 (en) 2019-01-23
BR112014002200A2 (pt) 2017-03-07
PT2739153T (pt) 2018-11-28
EA201400178A1 (ru) 2014-11-28
US20170087132A1 (en) 2017-03-30
US20190262315A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
MX359664B (es) Tratamiento de cáncer de mama.
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MA40076A (fr) Inhibiteurs de syk
DOP2015000083A (es) Modulación de la expresión de receptores androgénicos
IN2015DN03795A (es)
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
MX2013008212A (es) Derivados de 7-azaindol.
NZ723971A (en) Methods and compositions for treating ewings sarcoma family of tumors
EA201390756A1 (ru) Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний
IN2015DN00438A (es)
MX2014014832A (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
PH12015501088A1 (en) Dimeric compounds
MX2019010098A (es) Antiandrogenos para el tratamiento del cancer de prostata resistente a la castracion no metastasico.
MX2013007268A (es) Activadores de pkm2 bicíclicos.
MX359210B (es) Composición de combinación de pac-1 y tamoxifeno.
MX2014008864A (es) Derivados de triazolo[4,5-d]pirimidina.
MX364002B (es) Compuestos y composiciones activadoras de enzima.
SG10201900564WA (en) Methods for treating cancer
MX2016008042A (es) Derivados de imidazopirazinona.
WO2014110163A3 (en) Melk regulation for the treatment of breast cancer
IN2014MN01944A (es)

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ARESCO TECHNOLOGIES, LLC

FG Grant or registration